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Abstract
Entry of hepatitis C virus (HCV) into hepatocytes is a multi-step process that involves a number of different host cell factors.
Following initial engagement with glycosaminoglycans and the low-density lipoprotein receptor, it is thought that HCV
entry proceeds via interactions with the tetraspanin CD81, scavenger receptor class B type I (SR-BI), and the tight-junction
proteins claudin-1 (CLDN1) and occludin (OCLN), culminating in clathrin-dependent endocytosis of HCV particles and their
pH-dependent fusion with endosomal membranes. Physiologically, SR-BI is the major receptor for high-density lipoproteins
(HDL) in the liver, where its expression is primarily controlled at the post-transcriptional level by its interaction with the
scaffold protein PDZK1. However, the importance of interaction with PDZK1 to the involvement of SR-BI in HCV entry is
unclear. Here we demonstrate that stable shRNA-knockdown of PDZK1 expression in human hepatoma cells significantly
reduces their susceptibility to HCV infection, and that this effect can be reversed by overexpression of full length PDZK1 but
not the first PDZ domain of PDZK1 alone. Furthermore, we found that overexpression of a green fluorescent protein
chimera of the cytoplasmic carboxy-terminus of SR-BI (amino acids 479–509) in Huh-7 cells resulted in its interaction with
PDZK1 and a reduced susceptibility to HCV infection. In contrast a similar chimera lacking the final amino acid of SR-BI
(amino acids 479–508) failed to interact with PDZK1 and did not inhibit HCV infection. Taken together these results indicate
an indirect involvement of PDZK1 in HCV entry via its ability to interact with SR-BI and enhance its activity as an HCV entry
factor.
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Introduction
It is estimated that approximately 170 million people worldwide
are infected with hepatitis C virus (HCV); a major cause of serious
liver disease. At present there is no preventative vaccine available
and the widely preferred treatment regime of pegylated interferon
alpha (IFN-a) and ribavirin in combination is expensive, causes
adverse side effects and is only effective for a fraction of
individuals. Despite significant advances in identification of novel
antiviral agents that inhibit HCV replication and polyprotein
processing, concerns remain regarding the toxicity of these
compounds and the likelihood of development of antiviral
resistance [1]. The rapidly increasing understanding of the HCV
entry process and significant advances in the development and
application of HIV entry inhibitors (for review see [2]) have lead to
a growing appreciation that HCV entry is another promising
target for future antiviral therapies.
The recent development of the retroviral HCV pseudoparticle
system (HCVpp), in which HCV E1E2 glycoproteins are
assembled onto retroviral cores [3,4,5], and the infectious HCV
cell culture (HCVcc) system, in which the full viral lifecycle is
recapitulated in cell culture [6,7,8], have allowed in-depth analysis
of the HCV entry process. At present there is strong evidence to
suggest that the essential HCV entry factors include the
tetraspanin CD81 [5,9,10,11], the class B scavenger receptor
SR-BI [9,12,13,14], and the tight-junction proteins claudin-1 and
occludin [15,16,17,18,19,20]. Considering that these proteins may
comprise the complete set of essential HCV entry factors [18], it
still remains to be determined what the relative involvement of
each of these entry factors is and, beyond expression, what
secondary factors influence the contribution of these proteins to
HCV entry.
SR-BI is the major receptor for high-density lipoproteins (HDL)
and mediates both bi-directional flux of free cholesterol between
cells and lipoproteins and selective uptake of cholesteryl esters into
cells from HDL (reviewed in [21]). The latter function is of greatest
significance in the liver and steroidogenic tissues [22,23], where
SR-BI is most highly expressed [24]. Studies using rodents have
revealed that hepatic SR-BI expression is subject to little
transcriptional regulation but instead is largely regulated at the
post-transcriptional level by its interaction with the cytoplasmic
adaptor molecule PDZK1 (reviewed in [25]).
PDZK1, which is also known as NHERF3, CAP70, CLAMP
and NaPi-Cap1, is a four PDZ domain-containing adaptor protein
that is predominantly expressed in the liver, kidney and small
intestines [26]. Since the demonstration that the extreme C-
terminus of SR-BI interacts with the first N-terminal PDZ domain
of PDZK1 [26,27], a number of in vivo and in vitro studies have
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membrane content of SR-BI and its activity as an HDL receptor in
hepatocytes. Strikingly, in PDZK1 knockout (KO) mice, hepatic
levels of SR-BI protein are reduced by greater than 95% and
plasma HDL-cholesterol is elevated [28] to a level that approaches
those levels seen in SR-BI KO mice [29]. Although these effects
suggested the involvement of PDZK1 in regulating the stability of
SR-BI and its effective targeting to the plasma membrane in
hepatocytes, further studies have since revealed that hepatic
overexpression of SR-BI in SR-BI/PDZK1 double knockout mice
results in effective targeting of SR-BI to the hepatocyte plasma
membrane and restoration of apparently normal lipoprotein
metabolism [30]. The authors of this work therefore concluded
that PDZK1 is not essential for the correct localization and
function of SR-BI in the liver but instead is required for
maintenance of ‘steady state levels’ of hepatic SR-BI protein [30].
Recently the importance of PDZK1/SR-BI interaction to the
total hepatic abundance, plasma membrane content and activity in
lipoprotein metabolism of SR-BI has been further dissected by
studies involving the hepatic overexpression of C-terminally
truncated PDZK1 mutants in transgenic mice [31,32]. While
overexpression of the first PDZ domain (PDZ1) of PDZK1 could
not rescue normal SR-BI expression and activity in PDZK1 KO
mice, overexpression of PDZ1 in wildtype mice resulted in
cytoplasmic retention of endogenous SR-BI and a commensurate
effect on lipoprotein metabolism [32]. Further studies revealed
that transgenic expression of all four PDZ domains of PDZK1 is
required to restore normal SR-BI protein abundance, plasma
membrane content and activity in lipoprotein metabolism in
PDZK1 KO mice [31]. Collectively these results indicate that
interaction of the C-terminus of SR-BI with PDZK1, in itself, is
not sufficient to enhance total SR-BI expression, plasma
membrane localization and function. Instead other features of
PDZK1 appear to be necessary for its impact on SR-BI expression
and function. These may include phosphorylation of Ser-509 in
the C-terminus of PDZK1, which is associated with increased SR-
BI abundance in rat hepatoma cell culture [33] and/or association
with other proteins in a macromoleular complex.
The importance of the cytoplasmic carboxy-terminus of SR-BI
to its involvement in HCV entry has been examined in two recent
studies [12,13]. Firstly, Grove et al reported that soluble E2
binding and HCVcc infection levels are enhanced by overexpres-
sion of SR-BI or SR-BII, a splice-variant of SR-BI which features
an alternative cytoplasmic carboxy terminus [13]. However,
overexpression of SR-BI was associated with increases in HCVcc
infection levels that were several-fold higher than those observed
for overexpression of SR-BII [13], suggesting that features of the
cytoplasmic tail dictate the molecule’s efficient involvement in
HCV entry. Secondly, it has recently been reported that
complementation of SR-BI expression in rodent hepatoma cells
co-expressing human CD81 and claudin-1 rendered these cells
susceptible to infection with HCVpp and that this effect was
limited when SR-BI constructs bearing various mutations in the
cytoplasmic carboxy-terminus were substituted [12]. In that study,
however, the extreme carboxy-terminus of SR-BI and expression
of PDZK1 were not found to be significant determinants of HCV
entry levels.
In the present study we have examined the association of
human SR-BI and PDZK1 and how this impacts upon HCV entry
and replication. Specifically we show that the association between
SR-BI and PDZK1 is important for efficient entry of HCV into
hepatoma cells and suggest that disruption of this interaction may
be a future target of anti-HCV therapy.
Results
Domains and residues involved in PDZK1/SR-BI
association and subcellular localization
To date studies of the interaction of SR-BI and PDZK1 and the
functional significance of this interaction have been performed
using rodents and rodent-derived cell lines. To confirm the
interaction of human SR-BI and PDZK1 and to examine the
requirement of certain domains of each protein for the interaction,
co-immunoprecipitation (co-IP) experiments were performed. For
this, 293T cells were co-transfected with expression plasmids
encoding wildtype or mutant variants of SR-BI and PDZK1
(Figure 1A) prior to immunoprecipitation of FLAG-tagged
PDZK1 proteins and immunoblot detection of Myc-tagged SR-
BI proteins (Figure 1B; lower panel). In these experiments 293T
cells were used as they can be transiently transfected at high
efficiency, therefore allowing ready detection of overexpressed
proteins in whole cell lysates and immunoprecipitates. As
expected, wildtype SR-BI readily co-immunoprecipitated with
wildtype PDZK1, while a truncated SR-BI variant that lacks the
final carboxy-terminal lysine residue (mycSR-BID509) was not
detectable in immunoprecipitates of co-transfected wildtype
PDZK1. Furthermore we confirmed that the first amino-terminal
PDZ domain of PDZK1 (PDZ1) was sufficient to co-IP wildtype
SR-BI, with the NYGF motif present at amino acid residues 19–22
of PDZ1 being a predicted site of interaction with the carboxyl
terminus of SR-BI. Next we examined whether phosphorylation of
PDZK1 at Ser-505 impacted upon PDZK1/SR-BI association.
For the sake of consistency with the previous report of
phosphorylation of the corresponding site in rodent PDZK1
[33], this site will henceworth be referred to as Ser-509. While
mutation of this site (S509A and S509D) resulted loss of serine
phosphorylation in 293T cells (Figure 1C), both phosphodefective
(S509A) and phosphomimetic (S509D) mutants of PDZK1
associated with wildtype SR-BI with no apparent difference in
the relative amount of SR-BI that was co-immunoprecipitated
with these PDZK1 mutants (Figure 1B). Next, given that the C-
terminus of SR-BI has been implicated in its dimerization and
multimerization [34], we investigated whether the PDZK1-
interacting domain at the C-terminus of SR-BI was involved
in receptor dimerization. Co-IP studies in transfected 293T
Author Summary
Hepatitis C virus (HCV) infection is a major cause of serious
liver disease, with approximately 170 million people
infected worldwide. Although significant advances have
been made in the characterization and development of
novel therapeutics to combat HCV infection, there is still a
great need for an improved understanding of the HCV
lifecycle and potential future targets of antiviral therapy.
HCV entry into hepatocytes involves numerous plasma
membrane proteins including CD81, scavenger receptor
class B type I (SR-BI), claudin-1 and occludin. Although
these proteins may comprise the complete set of essential
HCV entry factors, the secondary factors that influence the
co-ordinated involvement of these proteins in HCV entry
remain to be determined. Here we identify the SR-BI
partner protein PDZK1 as an indirect regulator of HCV
entry. Our results indicate that binding of PDZK1 to the
cytoplasmic carboxy-terminus of SR-BI influences the
receptor’s involvement in HCV entry such that disruption
of this interaction may represent a future target of
therapeutic intervention.
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PLoS Pathogens | www.plospathogens.org 2 October 2010 | Volume 6 | Issue 10 | e1001130Figure 1. Interaction and colocalization of wildtype and mutant variants of SR-BI and PDZK1. (A) Schematic diagrams of PDZK1, SR-BI
and epitope-tagged wildtype and mutant derivatives of each. For SR-BI schematic diagrams transmembrane regions that flank the large extracellular
loop are depicted as white boxes. (B) Domains involved in SR-BI/PDZK1 interaction. 293T cells were co-transfected with the indicated SR-BI and
PDZK1 expression constructs prior to immunoprecipitation with anti-FLAG antibody and Western analysis of immunoprecipitates using anti-FLAG or
anti-Myc antibodies as indicated (lower panels). Note in immunoprecipitate samples PDZ1-FLAG (,18 kDa) was not distinguishable from light chain
bands (not shown). Expression of each of the FLAG- and Myc-tagged proteins, relative to the loading control b-actin, in whole cell lysates (WCL) prior
to IP is shown in the upper panel. (C) Detection of serine phosphorylation of PDZK1. 293T cells were transfected with the indicated PDZK1 expression
construct prior to immunoprecipitation (IP) with anti-FLAG antibody and Western analysis using anti-FLAG or anti-phosphoserine (SerP) antibodiesa s
indicated. (D) Laser-scanning confocal microscopy (LSCM) analysis of colocalization of overexpressed PDZK1 constructs and full-length SR-BI. Huh-7
cells were grown on gelatin-coated coverslips, transfected with the indicated expression constructs and processed for indirect immunofluorescent
detection of FLAG-tagged PDZK1 proteins (green) and SR-BI (red). Merged images (right panels) revealed colocalization (yellow). (E) LSCM analysis of
the localization of surface endogenous SR-BI (green) and overexpressed wildtype PDZK1-FLAG (red). Merged images (right panel) revealed
colocalization (yellow). For all conditions parallel samples were labelled with secondary antibody alone (surface SR-BI labelling) or isotype-matched
irrelevant control antibodies to confirm specificity of labelling (not shown).
doi:10.1371/journal.ppat.1001130.g001
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tagged full-length SR-BI and FLAG-SR-BID509, suggesting that
PDZK1-interaction is not involved in homodimerization of SR-BI
(Figure S1, A). Similarly, co-IP studies in Huh-7 cells confirmed
dimerization of FLAG-SR-BI with mycSR-BID509 and the ability
of mycSR-BI to interact with PDZK1-FLAG in this cell type
(Figure S1, B). Accordingly confocal analysis of the localization of
full length SR-BI and SR-BID509 revealed no appreciable
difference in the localization of these proteins in transfected
Huh-7 cells (Figure S1, C).
Finally, confocal analysis revealed extensive co-localization of
non-tagged wildtype SR-BI with FLAG-tagged PDZK1 in the
cytoplasm of transfected Huh-7 hepatoma cells (Figure 1D), with
no apparent effect of mutation of PDZK1 on its localization or co-
localization with SR-BI for each of the mutants S509A and
S509D. However, overexpressed PDZ1 displayed additional
nuclear localization, despite substantial co-localization with
cytoplasmic SR-BI. To reveal the localization of surface-displayed
endogenous SR-BI with respect to overexpressed PDZK1-FLAG,
transfected Huh-7 cells were fixed with formalin and SR-BI was
labelled by indirect immunofluorescence with an antibody that
recognizes the extracellular loop of SR-BI (and SR-BII) prior to
subsequent fixation, permeabilization and labelling of PDZK1-
FLAG (Figure 1E). These studies revealed a small degree of
overlap in the localization of surface SR-BI and PDZK1-FLAG
that was most evident at sites of cell-cell contact. Taken together
these experiments demonstrate that the interaction of SR-BI with
PDZK1 is not dependent on Ser-509 phosphorylation of PDZK1
and that the disruption of this interaction by truncation of SR-BI
cannot be attributed to an appreciable alteration in its localization.
Stable knockdown of PDZK1 expression in Huh-7
hepatoma cells inhibits HCV entry
Having confirmed that human SR-BI and PDZK1 interact we
next investigated the involvement of PDZK1 in entry of HCV
using stable shRNA-knockdown of endogenous expression of
PDZK1 in Huh-7 cells. Despite effective knockdown of PDZK1
expression, total SR-BI protein levels were not significantly altered
(Figure 2A). Furthermore, cell-surface biotinylation experiments
demonstrated that SR-BI remained readily detectable in strepta-
vidin precipitates of plasma membrane proteins in PDZK1-
knockdown cell lines (Figure 2B). Interestingly PDZK1 was co-
precipitated with biotinylated plasma membrane proteins purified
from control shRNA-expressing cells, but not from PDZK1
knockdown cells indicating that residual endogenous PDZK1 in
the latter cells is not preferentially plasma membrane-associated
(Figure 2B). Since PDZK1 has no transmembrane domains it is
likely that enrichment of PDZK1 in streptavidin precipitates in
these studies is the result of its association with the cytoplasmic tail
of SR-BI at the inner leaflet of the plasma membrane and possibly
other transmembrane partner proteins present in these cells.
Furthermore, flow cytometric analysis of surface levels of SR-BI
and splice variant SR-BII revealed no impact of PDZK1
knockdown on surface levels of these proteins (Figure 2C).
Likewise surface levels of CD81 were not significantly altered by
PDZK1 knockdown (Figure 2C). Interestingly, confocal analysis of
surface-labelled cells revealed extensive colocalization of SR-BI
and CD81 which was not appreciably altered by PDZK1
knockdown (Figure S2, A). Similarly we did not note any changes
in the staining pattern of occludin in PDZK1 knockdown cells
compared to control cells (Figure S2, B). Given that the
extracellular domain of SR-BI is shared by splice-variant SR-BII
[35], experiments involving confocal analysis of the localization of
intracellular SR-BI and surface SR-BI/II in the same samples
were undertaken to confirm that the majority of surface SR-BI/II
staining is also co-stained with an antibody directed against the
SR-BI-specific cytoplasmic C-terminus (Figure S3). From these
images it was also apparent that PDZK1 knockdown does not
cause an appreciable shift in the proportion of intracellular and
surface SR-BI staining. Together these results indicate that near-
complete loss of PDZK1 expression in Huh-7 cells does not
significantly alter total or surface levels of SR-BI or its localization
with respect to other requisite entry factors CD81 and occludin at
the cell surface.
Next we investigated the influence of stable knockdown of
PDZK1 expression in Huh-7 cells on HCV entry and replication.
Following infection of these cells with cell culture propagated
HCV (HCVcc; JFH-1), HCV RNA levels were approximately
40% lower in the PDZK1-knockdown cell lines compared to cells
that expressed a non-targeting shRNA control (Figure 3A).
Likewise, the relative susceptibility of these cells to HCVcc
infection was approximately 50% lower than control cells, as
determined by enumeration of HCV-positive foci (focus forming
units/ml; FFU/ml) following indirect immunofluorescent labelling
(Figure 3B). Similarly infection of these cells with Jc1/GFP or Jc1/
RFP infectious HCV chimeras, that bear the GFP- or RFP-coding
sequences inserted in-frame into domain III of NS5A of the
infectious genotype 2a chimera Jc1 [36], and flow cytometric
analysis of GFP- or RFP-associated epifluorescence revealed that
PDZK1-knockdown cells were approximately 80% (Jc1/GFP) and
60% (Jc1/RFP) less susceptible to infection with these chimeras
than their control counterparts (Figures 3C and 3D). To confirm
that the observed effects were attributable to an impact of
PDZK1-knockdown on HCV entry, and not an effect on HCV
replication or spread, HCVpp (H77s) entry into these cells was
measured. As for HCVcc infections, HCVpp entry was signifi-
cantly reduced by PDZK1 knockdown (Figure 3E). In these
experiments VSVG-pseudoparticle infection levels were un-
changed by PDZK1 knockdown, indicating that PDZK1 knock-
down causes HCV-specific inhibition of viral entry. Further
evidence that HCV entry, and not HCV replication, is limited by
PDZK1 knockdown was provided by the demonstration that
stable knockdown of PDZK1 expression in Huh-7 cells that
harbour the genome-length NNeo/C-5B(RG) replicon did not
significantly impact upon HCV RNA levels or HCV-associated
immunofluorescence (Figure S4). From these experiments we
conclude that expression of PDZK1 contributes to HCV entry into
Huh-7 cells most probably via an influence on its binding partner
SR-BI despite no dramatic effects on total or cell surface levels of
SR-BI protein. Given our observations that PDZK1 knockdown is
associated with decreased HCV entry levels for both genotype 1a
(HCVpp) and 2a (HCVcc) infection systems and the high degree of
divergence between E1/E2 sequences for these genotypes, it is
likely that the observed involvement of PDZK1 will hold true for
all HCV genotypes. However, it has been reported that the
relative involvement of SR-BI in HCV entry can differ between
HCV genotypes and subtypes [37] and thus the relative influence
of PDZK1 on SR-BI-dependent HCV entry may differ between
HCV genotypes/subtypes accordingly.
The impact of PDZK1 knockdown on HCV entry in
polarized HepG2 hepatoma cells
Given the contrasting effects on total and cell surface SR-BI
protein levels of PDZK1 knockdown in Huh-7 cells and PDZK1
gene knockout in mice [28] and the past demonstration that
ectopically expressed SR-BIdel509 functions similarly to wildtype
SR-BI in transfected cell lines but is unstable and mislocalized in
transgenic mouse liver [27], we set about generating a polarized
Regulation of Hepatitis C Virus Entry by PDZK1
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accurately reflect the in vivo liver situation than non-polarized
Huh-7 cells. To this end we stably overexpressed CD81 in the
HepG2(N6) cell line, which displays simple columnar polarity
[38], to render these cells permissive to HCVcc and HCVpp
infection [9,11,39,40]. Following confirmation of high-level cell
surface expression of CD81 (not shown), these cells were stably
transduced with PDZK1-specific or non-target control lentiviral
shRNA vectors. As for Huh-7 cells, stable knockdown of
endogenous PDZK1 expression in HepG2(N6)+CD81 cells that
had been grown under polarizing conditions (5 days post-
confluency) did not significantly alter total levels of SR-BI protein
(Figure 4A). Likewise there was no discernable impact of PDZK1
knockdown on cell surface levels of SR-BI or CD81, as determined
by Western analysis following cell-surface biotinylation and
streptavidin precipitation of plasma membrane associated proteins
(Figure 4B). However, we found that PDZK1 knockdown was
associated with a moderate yet significant reduction in the
susceptibility of HepG2(N6)+CD81 cells to HCVcc (Jc1/Myc)
infection (not shown). Moreover HCVpp infection was substan-
tially reduced in confluent HepG2(N6)+CD81 cells that expressed
PDZK1-specific shRNA’s compared to control shRNA-expressing
counterparts (Figure 4C). Taken together these results demon-
strate that knockdown of endogenous PDZK1 expression in
HepG2(N6)+CD81 cells results in their reduced susceptibility to
HCV infection.
Overexpression of full-length PDZK1 restores efficient
HCVcc entry in PDZK1-knockdown Huh-7 cells
To further confirm the involvement of PDZK1 in HCV infection
we generated a lentiviral PDZK1-FLAG expression construct
bearing silent mutations (S
tca261S
agc) to render the encoded
transcripts refractory to shRNA silencing by PDZK1 shRNA#5.
This construct was then overexpressed in both non-target shRNA
Figure 2. Stable knockdown of PDZK1 expression in Huh-7 cells. (A) Huh-7 cells were stably transduced with lentiviral shRNA expression
vectors encoding a non-target shRNA control or shRNA’s specific for PDZK1 (4 and 5), before Western analysis of expression of PDZK1 (,70 kDa) and
SR-BI (,85 kDa). b-actin (,42 kDa) was used as a loading control. PDZK1 and SR-BI protein levels were quantified by densitometry and normalized to
those of the loading control b-actin (graphs). Data are means + SEM (n=3). (B) Cell-surface expression levels of SR-BI. Huh-7 cells expressing the
indicated shRNA targets were surface-biotinylated prior to detergent lysis, streptavidin-precipitation of biotinylated proteins and Western blotting.
SR-BI and PDZK1 protein levels in whole cell lysates (WCL) (upper panels) and streptavidin-precipitates (lower panels) are shown. (C) Flow cytometric
analysis of surface levels of SR-BI/II (left panel gray histograms) and CD81 (right panel gray histograms) in Huh-7 shRNA cell lines. Background
fluorescence levels (black histograms) were determined by labelling cells with secondary antibody only (SR-BI staining) or an irrelevant isotype-
matched control antibody (CD81 staining). Results are representative of two separate experiments performed in triplicate.
doi:10.1371/journal.ppat.1001130.g002
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whether overexpression of the shRNA-refractory PDZK1 construct
would impact upon HCVcc infection and whether ‘normal’ levels of
HCVcc infection could be restored. In these experiments a PDZ1-
FLAGlentiviral expression construct servedas an additional control
that was expected to interact with the C-terminus of SR-BI but not
restore PDZK1 function in PDZK1 knockdown cells. Following
generation of stable cell lines using these vectors Western analysis
showed strong expression of PDZK1-FLAG and PDZ1-FLAG that
was comparable between each of the cell lines and did not alter total
endogenous SR-BI protein levels (Figure 5A), while parallel
immunofluorescent labelling of the overexpressed FLAG-tagged
proteins indicated that over 70% of cells expressed these constructs
for each of the cell lines (not shown).
Infection of these cells with HCVcc (Jc1/Myc) and quantifica-
tion of HCV-positive foci three days later revealed that
overexpression of full-length PDZK1 significantly increased
HCVcc infection levels in shRNA control cell lines and restored
levels of HCVcc infection in PDZK1 shRNA#5-expressing cells
to levels approaching those of the parental non-target shRNA
control cells (Figure 5B). In contrast to the effects of overexpression
of full-length PDZK1-FLAG, overexpression of PDZ1-FLAG did
not restore HCVcc infection levels in PDZK1 shRNA#5 cells to
those of non-target shRNA control cells. Given that hepatic
expression of a similar murine PDZ1 construct is reported to cause
mislocalization of endogenous SR-BI in transgenic mice and a
commensurate effect on HDL metabolism [32], we anticipated
that overexpression of PDZ1-FLAG would have a similar
dominant-negative effect on HCVcc infection. In contrast we
did not observe any significant impact of PDZ1-FLAG expression
on the susceptibility of either non-target shRNA- or PDZK1
shRNA-expressing cells to HCVcc infection. However, we have
observed that the PDZ1 polypeptide used in this study appears
somewhat instable compared to full-length PDZK1 (for example
see Figure 1B) and it is possible that high-level overexpression of
an alternative construct that encodes a more stable PDZ1 variant
may cause the inhibitory effects on HCV entry that were
predicted. Taken together these data indicate that the ability of
PDZK1 to enhance HCV infection requires regions of the protein
that lie outside the SR-BI-interacting domain of the molecule.
The cytoplasmic carboxy-terminus of SR-BI is sufficient to
interact with PDZK1 and influence the subcellular
localization of a soluble reporter
To further investigate the domains of each protein involved in
SR-BI/PDZK1 association and to investigate the validity of a
Figure 3. HCV entry is inhibited by stable knockdown of PDZK1 expression in Huh-7 cells. (A) Huh-7 cells stably expressing a non-target
control shRNA or PDZK1-specific shRNA constructs (#4 and #5) were incubated with HCVcc (JFH1; approximate multiplicity of infection: 0.1) for 3 h
prior to washing and return to culture for 72 h. HCV RNA levels, normalized to those of the cellular housekeeping gene RPLPO, were quantified by
real-time RT-PCR and expressed as a percentage of control HCV RNA levels. (B) Huh-7 cells expressing the indicated shRNA constructs were incubated
with HCVcc (JFH1; approximate multiplicity of infection: 0.1) for 3 h, washed and returned to culture for 72 h prior to enumeration of NS5A-positive
foci of infected cells. Virus infectivity is expressed relative to those of cells expressing the non-target shRNA control. (C and D) Huh-7 shRNA cell lines
were incubated with HCVcc (Jc1/GFP [C] of Jc1/RFP [D]) for 72 h prior to quantification of NS5A-associated epifluorescence (GFP or RFP) by flow
cytometry. HCVcc infection levels are expressed relative to those of cells expressing the non-target shRNA control. (E) Huh-7 cells expressing the
indicated shRNA constructs were challenged with HCVpp and VSVGpp encoding Luciferase reporters, washed and returned to culture for 72 h prior
to quantification of luciferase activity. Specific HCVpp and VSVpp infectivity levels were calculated by subtraction of the signals associated with non-
enveloped pseudoparticles (Env-pp). Values are expressed relative to infectivity levels for cells expressing the control non-target shRNA. For each
graph data are means + SEM (n=4). *, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.ppat.1001130.g003
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terminal 30 amino acids of the cytoplasmic carboxy-terminus of
wildtype SR-BI (WT-ctt) were appended in-frame to the carboxy-
terminus of enhanced green fluorescent protein (EGFP). As for
full-length SR-BI, the EGFP-WT-ctt chimera was readily
detectable in co-immunprecipitates of co-transfected wildtype
PDZK1 (Figure 6A). Importantly, a control chimera that lacked
the final C-terminal lysine residue (EGFP-D509-ctt) did not co-IP
with wildtype PDZK1. As for full-length SR-BI, EGFP-WT-ctt
was co-immunoprecipitated with wildtype PDZK1, PDZ1,
PDZK1 S509A and PDZK1 S509D.
Next, Huh-7 cell lines that stably express EGFP, EGFP-WT-ctt
or EGFP-D509-ctt were generated. Confocal analysis of the
localization of these fluorescent protein chimeras revealed that
EGFP-WT-ctt localized to distinct cytoplasmic punctae that
partially co-localized with LAMP1, a resident protein of late
endosomes and lysosomes (Figure 6B). In contrast, EGFP-D509-
ctt, which does not interact with PDZK1, was indistinguishable in
localization to unmodified EGFP (Figure S5, B), suggesting that
the distinctive punctate cytoplasmic localization of EGFP-WT-ctt
could be attributed to its ability to interact with endogenous
PDZK1. Western analysis of these cells revealed that stable
expression of EGFP-WT-ctt had no significant effect on the total
endogenous PDZK1 and SR-BI content in Huh-7 cells compared
to cells that stably expressed unmodified EGFP or EGFP-D509-ctt
(Figure 6C). Similarly, cell surface levels of SR-BI were not
appreciably altered by expression of EGFP-WT-ctt, compared to
those of cell lines expressing EGFP or EGFP-D509-ctt (Figure S5,
A). Nevertheless we reasoned that EGFP-WT-ctt would interact
with endogenous PDZK1 and, at high expression levels, out-
compete endogenous SR-BI for PDZK1 binding. In agreement
with this theory Huh-7 cells that stably expressed EGFP-WT-ctt
were nearly 50% less susceptible to HCVcc infection than native
EGFP-expressing control counterparts and nearly 80% less
susceptible to HCVcc infection than Huh-7 cells stably expressing
EGFP-D509-ctt (Figure 6D). Altogether these results indicate that
expression of the cytoplasmic carboxy terminus of SR-BI, as a
fusion to a soluble reporter, causes an inhibition of HCVcc
infection that can be attributed to its ability to bind PDZK1.
Discussion
Recent studies have indicated that the intracellular domains of
SR-BI, particularly the cytoplasmic C-terminus, contribute to the
activity of the receptor in HCV entry [12,13], indicating that the
binding of HCV to the extracellular domain of SR-BI, in itself, is
not sufficient for the efficient involvement of SR-BI in the HCV
entry process. Instead the cytoplasmic regions of the molecule may
dictate dynamic changes in receptor localization and/or interac-
tions with other HCV entry factors that facilitate HCV entry. In
the context of studies of the involvement of SR-BI in HDL
metabolism in mice, tissue-specific interaction of the cytoplasmic
C-terminus of SR-BI with the adaptor protein PDZK1 has
emerged as an important determinant of the receptor’s effective
enrichment at the hepatocyte plasma membrane and activity in
HDL-CE transport (reviewed in [25]).
Figure 4. Stable knockdown of PDZK1 expression in HepG2(N6)+CD81 cells. (A) HepG2(N6)+CD81 cells expressing the indicated shRNA
constructs were cultured under polarizing conditions (5 d post-confluence) prior to Western analysis of PDZK1 (,70 kDa) and SR-BI (,85 kDa)
protein levels. b-actin (,42 kDa) was used as a loading control. PDZK1 and SR-BI protein levels were quantified by densitometry and normalized to
those of the loading control b-actin (graphs). Data are means + SEM (n=3). (B) Cell-surface expression levels of SR-BI. HepG2(N6)+CD81 cells (5 d
post-confluence) expressing the indicated shRNA targets were surface-biotinylated prior to detergent lysis, streptavidin-precipitation of biotinylated
proteins and Western blotting. SR-BI, PDZK1 and CD81 (,26 kDa) protein levels in whole cell lysates (WCL) (upper panels) and streptavidin-
precipitates (lower panels) are shown. Overexpressed CD81 (with a C-terminal Myc epitope tag) was detected with an anti-C-myc antibody. (C)
Confluent HepG2(N6)+CD81 cells expressing the indicated shRNA constructs were infected with HCVpp or VSVpp 72 h prior to measurement of
luciferase activity. Data are means + SEM (n=4).
doi:10.1371/journal.ppat.1001130.g004
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human variants of SR-BI and PDZK1 and the importance of this
interaction to HCV entry. We have confirmed the interaction of
SR-BI with PDZK1 and provide evidence that the extreme C-
terminus of SR-BI and the first PDZ domain of PDZK1 are
critical sites of the interaction. Accordingly these proteins were
found to overlap extensively in subcellular localization in the
cytoplasm of transfected Huh-7 cells, with no discernable impact
of mutation of the sites of interaction in both proteins or the major
site of phosphorylation of PDZK1 on the colocalization of these
proteins. While it has been reported that the protein kinase A
(PKA)-dependent phosphorylation of the corresponding serine
residue in rat PDZK1 is necessary for the ability of overexpressed
PDZK1 to increase endogenous SR-BI protein levels in Fao
hepatoma cells [33], we found no discernable impact of
phosphodefective or phosphomimetic mutations at this site on
the interaction or localization of these proteins, suggesting that
phosphorylation at this site causes more subtle effects on SR-BI
biology in human hepatocytes. It will be interesting to examine the
relative importance of phosphorylation of PDZK1 to the
involvement of SR-BI in the HCV entry process.
Effective knockdown of PDZK1 expression in Huh-7 cells was
associated with a decreased susceptibility of these cells to infection
with HCVcc and HCVpp, despite no discernable impact on total
or surface levels of SR-BI protein. These effects contrast the more
dramatic effects of PDZK1-knockout on the SR-BI protein
content in mouse liver [28] and suggest that the plasma
membrane-associated SR-BI in these cells is impaired in its ability
to facilitate HCV entry. It is possible that loss of interaction with
PDZK1 alters the localization of SR-BI within the plasma
membrane. For example, it has been reported that SR-BI localizes
to caveolae, a specialized subset of lipid raft domains of the plasma
membrane, and that this localization may be important to the
receptor’s activity [41]. Consistent with this theory, removal of
membrane raft cholesterol with MbCD inhibits HCV entry [42].
However, it has also been reported that neither SR-BI, nor other
requisite entry factors CD81 and claudin-1, are strongly associated
with plasma membrane lipid raft-enriched detergent-resistant
membranes (DRMs) of Huh-7 cells [43]. Our analysis of the
localization of SR-BI revealed that SR-BI staining, which was
largely cytoplasmic, frequently colocalized CD81 at the cell
surface and this colocalization was not appreciably altered by
PDZK1 knockdown. Similarly, we did not observed any marked
effects of PDZK1 knockdown on the staining pattern of occludin.
Based on what is known of the kinetics of antibody-mediated
inhibition of HCV entry [15,44,45] and the differences in the
localization of the four major HCV entry factors in human liver
and hepatoma cells that support HCV entry [39,46,47], it has
been suggested that SR-BI and CD81 are involved in post-binding
steps of HCV entry, after which lateral migration of virus/receptor
complexes towards tight junctions occurs and interaction with
CLDN1 and occludin takes place.
Tight junctions are likely to be largely inaccessible to HCV
under normal physiological conditions. Indeed, recent studies
involving the use of the colorectal adenocarcinoma cell line Caco-
2 that develops simple columnar polarity and HepG2 hepatoma
cells that develop complex hepatic polarity have demonstrated that
the formation of genuine tight junctions between cells as they
develop polarity results in restricted access to viral receptors and
inhibition of HCV entry [39,48]. Interestingly, however, disrup-
tion of the integrity of tight junctions of polarized HepG2-CD81
cells with inflammatory cytokines does not perturb cell polarity or
enhance HCV entry, whereas phorbol ester-induced activation of
protein kinase C (PKC) results in both disruption of junctional
integrity and cellular polarity and enhancement of HCV entry
[39]. Similarly cAMP-dependent activation of protein kinase A
(PKA) has also been shown to be important to HCV entry, with
inhibition of PKA activity causing redistribution of CLDN1 to
intracellular sites, disruption of CLDN1 association with CD81
and inhibition of HCV entry [49]. Intriguingly PKA activation is
also associated with phosphorylation of PDZK1 [33], suggesting
that the effects of PKA activity on HCV entry may also coincide
with PDZK1-dependent changes in the involvement of SR-BI in
the entry process. This possibility warrants further investigation.
The involvement of HCV itself in the disruption of tight junctions
and enhancement of HCV entry is also gaining attention. For
example, HCV infection has been associated with disruption of the
localization of claudin-1 and occludin to sites of cell-cell contact
Figure 5. Expression of full-length PDZK1 restores normal
HCVcc infection levels in PDZK1-knockdown Huh-7 cells. (A)
Huh-7 cells expressing the indicated shRNA construct were stably
transduced with shRNA-refractory PDZK1-FLAG or PDZ1-FLAG expres-
sion constructs prior to Western blot analysis of FLAG-tagged transgene
and SR-BI protein levels. b-actin was used as a loading control. (B) Huh-7
cells stably expressing the indicated shRNA and cDNA constructs were
incubated with HCVcc (Jc1/Myc; approximate multiplicity of infection:
0.3) for 3 h, washed and returned to culture for 72 h, prior to detection
of NS5A-positive foci of infected cells by immunofluorescence using an
anti-Myc antibody. Virus infectivity is expressed as the number of focus-
forming units (FFU)/ml. Data are means + SEM (n=4). Statistically
significant differences from parent cells expressing the non-target
shRNA control are indicated by asterisks (**, P,0.01; ns, not significant).
doi:10.1371/journal.ppat.1001130.g005
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heterodimerization with claudin-1 [51]. Furthermore, a recent
study has revealed that vascular endothelial growth factor (VEGF),
which is upregulated in HCV-infected hepatocytes, promotes
disruption of hepatocyte polarity and tight junctions between cells,
thereby increasing their susceptibility and the susceptibility of
Figure 6. A green fluorescent protein chimera of the SR-BI C-terminus interacts with PDZK1 and inhibits HCVcc infection. (A) 293T
cells were co-transfected with expression vectors encoding the indicated chimeric GFP-SR-BI cytoplasmic C-terminus (cct) (aa 479-509 or 479-508)
expression construct and PDZK1 expression construct prior to immunoprecipitation with anti-FLAG antibody and Western analysis of
immunoprecipitates using anti-FLAG or anti-GFP antibodies as indicated (right panels). Expression of each of the FLAG- and GFP-tagged proteins,
relative to the loading control b-actin, in whole cell lysates (WCL) prior to IP is shown in the left panel. (B) Laser-scanning confocal microscopy analysis
of the localization of EGFP-WT-ctt. Huh-7 cells stably expressing EGFP-WT-ctt were grown on gelatin-coated coverslips, transfected with the indicated
red fluorescent protein (RFP) expression construct (where applicable) and processed for direct detection of fluorescent protein-associated
epifluorescence or indirect immunofluorescent detection of LAMP1. Merged images are shown in the right panels. (C) Western analysis of SR-BI
(,85 kDa), PDZK1 (,70 kDa), EGFP (,25 kDa), EGFP-WT-ctt (,32 kDa) and EGFP-D509-ctt (,32 kDa) protein levels in Huh-7 cells stably expressing
the indicated EGFP construct. b-actin (,42 kDa) was used as a loading control. SR-BI and PDZK1 protein levels were quantified by densitometry and
normalized to those of b-actin (graph inset). Data are means + SEM (n=3). (D) Huh-7 cells stably expressing the indicated EGFP chimera were
incubated with HCVcc (Jc1/Myc; approximate multiplicity of infection: 0.3) for 3 h, washed and returned to culture for 72 h prior to quantification of
HCV RNA levels (normalized to RPLPO mRNA). HCV RNA levels are expressed relative to those of EGFP-expressing control cells. Data are means + SEM
(n=4). **, P,0.005; ***, P,0.001.
doi:10.1371/journal.ppat.1001130.g006
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determine whether disruption of cellular polarity and HCV
infection have any impact upon the subcellular localization of
SR-BI and PDZK1.
In argument against a rate-limiting role for PDZK1 in HCV
entry the degree of inhibition of viral entry observed in PDZK1-
knockdown Huh-7 cells (30-80%) did not closely reflect the degree
of knockdown of PDZK1 protein levels (.90%). Although it could
be argued that residual amounts of PDZK1 protein are sufficient
to partially compensate for the knockdown of the majority of
endogenous PDZK1 expression, we could not detect surface-
associated PDZK1 in streptavidin precipitates of biotinylated
plasma membrane proteins prepared from these cells indicating
that residual amounts of PDZK1 were not preferentially associated
with SR-BI at the cell-surface. Previously it was shown that a
truncated mutant of SR-BI (SR-BIdel509), that does interact with
PDZK1, was not readily detectable at the plasma membrane of
hepatocytes prepared from SR-BIdel509 transgenic mice, indicat-
ing that in polarized hepatocytes interaction with PDZK1 is
required for the correct localization of SR-BI [27]. Somewhat
paradoxically, hepatic overexpression of full-length SR-BI in
PDZK1-knockout mice can restore wildtype levels of total and
surface SR-BI protein and reverse the effects of PDZK1-knockout
on HDL metabolism [30], suggesting that alternative and likely
inefficient PDZK1-independent means for the effective enrich-
ment of full-length SR-BI at the hepatocyte plasma membrane
exist. Further studies involving the use of polarized hepatoma cells
or primary hepatocytes in which PDZK1 expression has been
ablated are required to accurately predict the relative importance
of PDZK1 to HCV infection in the human liver in vivo. Given
recent major advances in the identification of factors that
determine human hepatotropism of HCV entry [18] and
adaptation of HCVcc to murine CD81 [53], studies of HCV
entry into primary hepatocytes isolated from PDZK1-KO mice
and derivatives may be possible in the foreseeable future.
It has recently been reported that PDZK1-knockdown does not
have a substantial effect on HCVpp infection or HDL-mediated
enhancement of HCVpp infection [12]. Although the reasons for
the differences between the findings of that study and ours are not
obvious, it is possible that near-complete knockdown of endoge-
nous PDZK1 is required to observe inhibition of HCV entry. It is
also possible that, between Huh-7 cell derivatives, variations in the
relative levels of each of the HCV entry factors influences the
relative dependence on that protein for efficient HCV entry, such
that high levels of CD81, for example, could result in decreased
dependence on SR-BI for initial capture of cell-free virus.
Nevertheless, we employed additional overexpression and domi-
nant-negative strategies to further investigate the importance of
SR-BI/PDZK1 interaction to HCV entry. These studies revealed
that overexpression of full-length PDZK1 significantly increased
HCVcc infection levels in Huh-7 cells and restored baseline
HCVcc infection levels in Huh-7 cells displaying knockdown of
endogenous PDZK1. In contrast the SR-BI-interacting domain
(PDZ1) of PDZK1 alone was not sufficient to restore normal
HCVcc infection levels in PDZK1 knockdown cells indicating that
regions outside this domain are required. Relevant to this, all four
PDZ domains of PDZK1 are required to restore wildtype SR-BI
protein levels and function in lipoprotein metabolism in PDZK1
knockout mice [31]. The reasons that PDZ1 overexpression did
not have an inhibitory impact on HCVcc infection, as might be
expected given the dominant-negative effects of hepatic PDZ1
(amino acids 1–116) expression on SR-BI expression and function
in transgenic mice [32], are not clear. However the additional
nuclear localization of our PDZ1 construct (amino acids 1–130)
that was not observed in PDZ1-transgenic mice indicates the
presence of substantive differences between the constructs that
were not anticipated. Nevertheless, expression of the PDZK1-
interacting domain of SR-BI, as a GFP fusion protein, resulted in
reduced susceptibility of Huh-7 cells to HCVcc infection and a
cytoplasmic organellar localization of the fusion protein. We
therefore propose that pharmaceutical mimicry of this PDZK1-
interacting domain of SR-BI may represent a future target of anti-
HCV therapy which is relatively liver-specific.
Interestingly, like SR-BI, occludin and claudin-1 also interact
with PDZ domain-containing cytoplasmic adaptor molecules (ZO-
1 and ZO-2, respectively) via their cytoplasmic carboxy-termini
(reviewed in [54]). While knockdown of ZO-1 expression has been
associated with a decreased susceptibility of Huh-7 cells to HCV
entry [16], this effect was not observed in another similar study
[46]. Similarly, although C-terminally truncated claudin-1 can still
support HCV entry, this mutation was associated with an
approximately 3-fold reduction in HCV entry [15], suggesting
that the PDZ-interacting domain of claudin-1 contributes to its
efficient involvement in HCV entry. Interactions of SR-BI,
occludin and claudin-1 with their respective PDZ domain-
containing adaptor molecules at the inner leaflet of the plasma
membrane may be particularly important to their respective
localizations and activities in polarized hepatocytes in vivo.
Taken together our results indicate that the interaction of
PDZK1 with SR-BI contributes to the efficient infection of
hepatoma cells by HCVcc. Since the identification of what may
represent the complete set of essential HCV entry factors, it
remains to be determined when and how each of these proteins
participates in viral entry and the secondary factors that influence
dynamic changes in the localization and activity of each of the
HCV entry factors. Future studies of this nature will improve our
understanding of HCV infection and tropism and may reveal new
targets of antiviral therapy.
Materials and Methods
Cell culture
A Huh-7 cell line that is permissive to HCV infection and
replication was kindly provided by Eric Gowans (Children’s
Health Research Institute, Adelaide). Huh-7 cells harbouring the
genotype 1b NNeo/C-5B(RG) genomic HCV replicon [55] were
kindly provided by Stanley Lemon (University of Texas Medical
Branch, Galveston). The HepG2(N6) clone was kindly provided by
David Anderson (Macfarlane Burnet Institute, Melbourne). 293T
cells were obtained from the American Type Culture Collection.
With the exception of HepG2(N6) cells and their derivatives which
were culture as previously described [38], all cells were maintained
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 2 mM L-glutamine, non-essential amino acids, penicillin
(100 U/ml), streptomycin (100 mg/ml) and 10% foetal bovine
serum (FBS). Where appropriate, selective antibiotics G418
(800 mg/ml), puromycin (3 mg/ml) and/or blasticidin (3 mg/ml)
were added to culture media. All cells were cultured at 37uCi n5 %
CO2.
Antibodies and conjugates
Rabbit polyclonal antibodies against PDZK1 (Zymed Labora-
tories), SR-BI (Novus Biologicals), C-myc (Santa Cruz) and FLAG
(Sigma) were purchased. Mouse monoclonal antibodies against the
following antigens were purchased: FLAG (M2; Sigma), b-actin
(clone AC-15; Sigma), C-myc (clone 9E10; Roche Applied
Science), phosphoserine (clone 7F12; Invitrogen), CD81 (clone
JS81; Pharmingen), and occludin (clone OC-3F10; Zymed
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from Rockland Immunochemicals. Human anti-SR-BI monoclo-
nal antibody C-167 [56] was kindly provided by Alessandra Vitelli
(Istituto di Ricerche di Biologia Molecolare P. Angeletti, Rome).
Mouse monoclonal anti-NS5A antibody 9E10 was kindly provided
by Charles Rice (The Rockefeller University, New York). Alexa
Fluor-488 and -555 conjugated secondary antibodies were
purchased from Invitrogen. HRP-conjugated anti-mouse IgG
and anti-rabbit IgG antibodies and streptavidin-conjugated HRP
were from Pierce.
Plasmids and transfection
The following plasmids were generous gifts: pJFH-1 [7] (Takaji
Wakita; National Institute of Infectious Diseases, Shinjuku-ku),
pJc1/GFP and pJc1/RFP [36] (Ralf Bartenschlager; University of
Heidelberg, Heidelberg), pER-RFP and pGolgi-RFP [57] (Erik
Snapp; Albert Einstein College of Medicine, New York) and
pLenti6/V5-D-TOPO-tdTomato (Yuka Harata-Lee; University
of Adelaide, Adelaide). Plasmid pJc1/Myc was generated by in-
frame replacement (XbaI/RsrII) of the GFP coding region of pJc1/
GFP with an oligonucleotide adaptor duplex encoding the C-myc
epitope (EQKLISEEDL). PDZK1 cDNA (NM_002614) expres-
sion constructs with C-terminal FLAG (DYKDDDDK) epitope
tags, PDZK1-FLAG and PDZ1-FLAG (encoding aa 1–130), were
cloned into pcDNA3 (HindIII/XbaI) (Invitrogen) and pLenti6/V5-
D-TOPO (BamHI/XhoI) (Invitrogen). Where indicated mutations
encoding the amino acid substitutions S505A or S505D (referred
to as S509A and S509D for consistency with the original
description of Ser-509 phosphorylation in rat PDZK1 [33]), and
the silent mutation S
tca261S
agc were introduced by QuickChange
site-directed mutagenesis (Stratagene). Full-length and C-termi-
nally truncated (D509) SR-BI cDNA (NM_005505) expression
constructs, with or without N-terminal Myc or FLAG epitope tags,
were cloned into pcDNA6/V5-HisB (HindIII/XbaI) (Invitrogen).
EGFP-WT-ctt and EGFP-D509-ctt expression plasmids were
generated by cloning the cDNA region encoding the cytoplasmic
C-terminus of SR-BI (aa 479–509) with a Myc epitope tag at the
N-terminus into pcDNA3 (XhoI/XbaI). The EGFP coding
sequence, with the stop codon removed, was then cloned in-frame
into upstream restriction sites (EcoRI/XhoI). To generate pcDNA3-
EGFP the EGFP coding sequence, including the stop codon, was
cloned into pcDNA3 (EcoRI/XhoI). Plasmid pcDNA3-CD81myc
was generated by cloning CD81 cDNA (NM 004356), with a C-
terminal C-myc epitope tag, into pcDNA3 (HindIII/BamHI). All
constructs were confirmed by automated DNA sequencing. Exact
cloning details are available upon request. To generate
HepG2(N6) cell lines expressing CD81, HepG2(N6) cells were
transfected with pcDNA3-CD81myc using FuGene6 (Roche) as
per manufacturer’s instructions and, 48 h post-transfection, G418
(800 mg/ml) selection was applied. G418-resistant clones were
later individually expanded and screened for CD81 expression by
flow cytometry (not shown). One clone displaying uniform, high-
level expression of CD81 was chosen for further analysis. Huh-7
cells stably expressing EGFP, EGFP-WT-ctt or EGFP-D509-ctt
were generated by transfection with the corresponding pcDNA3
expression plasmid, selection with G418 and enrichment of GFP-
positive cells using a FACSAria flow cytometer (BD Biosciences).
Virus generation and infections
Cell culture propagated HCV particles (HCVcc; JFH-1, Jc1/
GFP, Jc1/RFP and Jc1/Myc) were generated as described
previously [8]. Briefly, in vitro transcribed HCV RNA was generated
from XbaI-linearized plasmid pJFH-1 or MluI-linearized plasmids
pJc1/GFP, pJc1/RFP or pJc1/Myc using a MEGAscript T7 kit
(Ambion). Huh-7 cells were electroporated with 10 mg of RNA and
at 5 d post-transfection (3 d post-transfection for Jc1/GFP and Jc1/
RFP preparations) virus containing supernatants were collected,
filtered (0.45 mm) and used undiluted to infect naı ¨ve cells for
3 hours. Cell monolayers were then washed twice with PBS and
returned to culture for 48–72 h, as indicated, prior to analysis of
HCV infection. HCVcc infectious titres (focus forming units
[FFU]/ml) were determined as described previously [8].
Pseudoviruses encoding Luciferase were generated by co-
transfection of 293T cells with the lentiviral packaging plasmids
psPAX2 (Addgene plasmid 12260), pRSV-Rev (Addgene plasmid
12253), pLenti6/V5-D-TOPO-Luciferase and either VSV-G
envelope expression plasmid pMD2.G (Addgene plasmid 12259)
for generation of VSVpp, the expression plasmid pE1E2H77c [4]
for generation of HCVpp or empty plasmid pcDNA3 for
generation of Env-pp. Supernatants were harvested at 48 and
72 h post-transfection, pooled and filtered (0.45 mm). Virus-
containing cell culture supernatants were then diluted in normal
culture media (1:500 for VSVpp, 1:2 for HCVpp and Env-pp) and
incubated with target cells, seeded at 2610
4 cells/cm
2 the day
before (unless otherwise specified), for 7 h before washing with
PBS and return to culture. Pseudoparticle infections were
performed in the presence of 4 mg/ml polybrene. At 72 h post-
infection luciferase activity was measured using a Luciferase Assay
System (Promega) and a GloMax 96 microplate luminometer
(Promega). Specific HCVpp and VSVpp infectivity levels were
determined by subtraction of the luciferase signals associated with
the use of non-enveloped pseudoparticles (Env-pp).
Lentiviral pLKO.1 shRNA constructs specific for human
PDZK1 were purchased from Open Biosystems (target set for
NM_002614).PDZK1-specificshRNAclones(PDZK1shRNA#4,
TRCN0000059671; PDZK1 shRNA#5, TRCN0000059672) and
a controlnon-target shRNA clone (Sigma; SHC002) were packaged
into lentiviral vectors by co-transfection of 293T cells along with
psPAX2 and pMD2.G. Lentiviral overexpression vectors were
generated by co-transfection of 293T cells with psPAX2, pMD2.G,
pRSV-Rev and either pLenti6/V5-D-TOPO-PDZK1-FLAG or
pLenti6/V5-D-TOPO-PDZ1-FLAG. Lentiviral supernatants were
collected at 48 and 72 h post-transfection, pooled, filtered (0.45 mm)
and stored at 280uC. Target cells were infected for 4 h with
lentiviral supernatants diluted 1:5 in normal culture medium
containing 8 mg/ml polybrene (Sigma). Antibiotic selection with
puromycin ([3 mg/ml] for pLKO.1constructs)or blasticidin ([3 mg/
ml] for pLenti6/V5-D-TOPO constructs) was applied 48 h later to
generate antibiotic-resistant polyclonal cell lines.
Laser scanning confocal microscopy
Huh-7 cells were grown on 0.2% gelatin-coated coverslips
overnight, transfected where applicable and fixed the following
day in ice-cold acetone:methanol (FLAG, Myc, NS5A) or ice-cold
5% buffered formalin (GFP/RFP epifluorescence, SR-BI, CD81,
occludin, LAMP1). Where appropriate, cells were permeabilized
with 0.05% saponin in PBS, prior to blocking in 5% BSA in PBS
and incubation with primary antibody diluted in 1% BSA in PBS
for 1 h at room temperature. After washing twice with PBS, Alexa
Fluor-488 and/or Alexa Fluor-555 conjugated secondary anti-
bodies were applied for 1 h at 4uC. Cell monolayers were then
washed twice with PBS and coverslips were mounted using
ProLong Gold antifade reagent (Invitrogen). Where combinations
of antibodies were used, control experiments using isotype-
matched irrelevant antibodies or secondary antibody alone (SR-
BI surface labelling) were performed to ensure minimal non-
specific binding of antibodies. Cells were viewed using an
Olympus IX70 inverted microscope linked to a Bio-Rad Radiance
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1.4NA water immersion lens (2–36 zoom) and images were
acquired sequentially for each fluorophore and processed using
Adobe Photoshop 6.0 software (Adobe Systems Inc).
HCV RNA quantitation
Extraction of total cellular RNA, first-strand cDNA synthesis
and real-time RT-PCR was performed as described [58].
Immunoprecipitation
Immunoprecipitation of FLAG-tagged proteins was performed
as follows. Near-confluent cells in 35 mm dishes were washed with
PBS before lysis in 0.5 ml of NP-40 lysis buffer (1% NP-40,
150 mM NaCl, 50 mM Tris [pH 8.0]) containing protease
inhibitors (Sigma) on ice for 30 min. Samples were then passed
through a 26 gauge needle 10 times and cleared of nuclear debris
by centrifugation (10,0006g, 10 min). All incubations were
performed at 4uC with end-over-end rotation. Lysates were pre-
cleared by incubation with 20 ml of protein A/G PLUS agarose
(Santa Cruz Biotechnology) for 1 h. Samples were then centri-
fuged (10006g, 5 min, 4uC) and supernatants were collected and
incubated with 1 mg of anti-FLAG mAb overnight. 20 mlo f
protein A/G PLUS agarose was then added to each sample prior
to incubation for 1 h. Beads were then pelleted by centrifugation
(10006g, 5 min, 4uC) and washed 5 times with 1 ml of NP-40 lysis
buffer before resuspension in 40 ml of SDS-PAGE loading buffer
and Western analysis.
Cell surface biotinylation and streptavidin precipitation
Biotinylation of plasma membrane proteins with membrane
impermeable sulfo-NHS-biotin (Pierce) and streptavidin-precipi-
tation of biotinylated proteins was performed as described
previously [59].
Western blotting
Cells were lysed in RIPA buffer (150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0)
containing protease inhibitors (Sigma) on ice for 30 min,
homogenized and cleared by centrifugation (10,0006g, 10 min).
For each sample approximately 30 mg of protein was separated by
12% SDS-PAGE and transferred to HyBond-ECL nitrocellulose
membrane (Amersham Biosciences) for immunoblotting using
anti-FLAG, anti-Myc, anti-GFP, anti-PDZK1, anti-SR-BI or anti-
b actin. HRP-conjugated secondary antibodies or HRP-conjugat-
ed streptavidin were detected by chemiluminescence using
SuperSignal West Femto (Pierce). Where indicated densitometric
analysis of bands was performed using NIH Image software.
Flow cytometry
Cells were harvested by trypsinization, washed (PBS/1%FBS) and
incubated at 4uC for 1 h with appropriately diluted anti-CD81, anti-
SR-BI (C-167), irrelevant isotype-matched control MAb (CD81
labelling) or no primary antibody (SR-BI labelling). Following
washing, cells were incubated for 1 h at 4uC with Alexa Fluor-555
conjugated goat anti-mouse IgG or Alexa Fluor-555 conjugated goat
anti-human IgG. Cells were then washed, fixed (1% formalin in PBS
containing 111 mM D-glucose and 10 mM NaN3)a n da n a l y s e d
using a FACS-Canto flow cytometer (BD Biosciences).
Statistical analysis
Data are expressed as means + the standard error of the mean
(SEM). Statistical analysis was performed by Student’s t test, with
P,0.05 considered to be statistically significant.
Accession numbers
PDZK1, NM_002614; SR-BI, NM_005505; CD81, NM_004356;
Claudin-1, NM_021101; Occludin, NM_002538; HCV (JFH-1),
AB047639; HCV (HC-J6), HPCPOLP; HCV (H77), NC_004102.
Supporting Information
Figure S1 Dimerization of SR-BI is independent of interaction
with PDZK1. (A) 293T cells were co-transfected with the indicated
epitope-tagged SR-BI expression vectors prior to immunoprecip-
itation of FLAG-tagged proteins and immunoblot detection of co-
immunoprecipitated Myc-tagged proteins (lower panel). Mutation
of the PDZK1-interacting domain of SR-BI (mycSR-BID509) did
not abrogate co-immunoprecipitation with FLAG-SR-BI or
FLAG-SR-BID509. (B) Huh-7 cells were co-transfected with the
indicated epitope-tagged SR-BI or PDZK1 expression vectors
prior to immunoprecipitation of FLAG-tagged proteins and
immunoblot detection of co-immunoprecipitated Myc-tagged
proteins (lower panel). These results suggest that dimerization of
SR-BI in Huh-7 cells does not involve PDZK1 interaction and
indicate that SR-BI/PDZK1 interaction occurs in Huh-7 cells as it
does in 293T cells. (C) Confocal analysis of the localization of
mycSR-BID509 with respect to FLAG-SR-BI (middle panels) and
PDZK1-FLAG (lower panels) revealed no discernable impact of
C-terminal truncation of SR-BI on its localization.
Found at: doi:10.1371/journal.ppat.1001130.s001 (0.96 MB TIF)
Figure S2 Colocalization of SR-BI with CD81 is unaffected by
PDZK1 knockdown. (A) Huh-7 cells expressing a non-target
control shRNA or PDZK1 shRNA #5 were grown on coverslips,
fixed and surface labelled with antibodies directed against SR-BI
(mAb C-167; green) and CD81 (red). Merged images revealed
extensive colocalization. (B) Alternatively these cells were fixed,
labelled with anti-SR-BI (green), fixed again and permeabilized
prior to indirect immunofluorescent labelling of occludin (red).
Merged images revealed minimal overlap in the localization of
these proteins. For these experiments z-sections (0.5 mm steps)
were collected and representative images for a single optical slice
are shown. For all combinations of antibodies parallel samples
were labelled with secondary antibody only (for SR-BI labelling) or
irrelevant isotype-matched control antibodies to confirm specificity
of labelling (not shown).
Found at: doi:10.1371/journal.ppat.1001130.s002 (4.38 MB TIF)
Figure S3 Cell surface and intracellular localizations of SR-BI in
Huh-7 cells expressing control or PDZK1-specific shRNAs. Huh-7
cells expressing a non-target control shRNA, PDZK1 shRNA #4
or PDZK1 shRNA #5 were grown on coverslips, fixed and
surface labelled with anti-SR-BI (mAb C-167; green). Cells were
then fixed again, permeabilized and labelled with a rabbit
polyclonal antibody directed against the C-terminus of SR-BI
(red). Merged images indicated that the majority of surface SR-BI/
II labelling can be attributed to SR-BI. For these experiments z-
sections (0.5 mm steps) were collected and representative images
for a single optical slice are shown. Parallel samples were labelled
with secondary antibody only (for SR-BI/II labelling) or irrelevant
rabbit antisera (for SR-BI labelling) to confirm specificity of
labelling (not shown).
Found at: doi:10.1371/journal.ppat.1001130.s003 (2.04 MB TIF)
Figure S4 HCV replication is unaffected by PDZK1 knock-
down. (A) Huh-7 cells that harboured the genomic HCV replicon
NNeo/C-5B(RG) were stably transduced with the indicated
lentiviral shRNA vector prior to Western analysis of total SR-BI
(,85 kDa) and PDZK1 (,70 kDa) protein levels. b-actin
(,42 kDa) served as a loading control. (B) Total RNA was
Regulation of Hepatitis C Virus Entry by PDZK1
PLoS Pathogens | www.plospathogens.org 12 October 2010 | Volume 6 | Issue 10 | e1001130extracted from these cells for real-time RT-PCR analysis of HCV
RNA levels, normalized to RPLPO mRNA. Data are means +
SEM (n=4). (C) Indirect immunofluorescence detection of HCV
antigens (using pooled antisera from HCV-infected individuals) in
Huh-7 cells harbouring the NNeo/C-5B(RG) replicon and
expressing the indicated shRNA constructs.
Found at: doi:10.1371/journal.ppat.1001130.s004 (0.70 MB TIF)
Figure S5 (A) Huh-7 cells stably expressing EGFP, EGFP-WT-
ctt or EGFP-D509-ctt were surface biotinylated prior to detergent
lysis and streptavidin precipitation of plasma membrane proteins.
Western analysis of streptavidin precipitates revealed no appre-
ciable impact of EGFP-WT-ctt expression upon surface levels of
SR-BI. (B) Confocal analysis of EGFP-D509-ctt localization in
Huh-7 cells. Huh-7 cells stably expressing EGFP-D509-ctt were
grown on coverslips, transfected with the indicated expression
plasmid (ER-RFP, Golgi-RFP, or RFP), fixed and processed for
laser scanning confocal microscopy. Alternatively these cells were
fixed and LAMP1 was labelled by indirect immunofluorescence
(bottom panels). EGFP-D509-ctt was indistinguishable from
unmodified EGFP in localization. Where appropriate parallel
samples of non-transfected cells and/or isotype control labelled
cells (for anti-LAMP1 labelling) were visualized to confirm
specificity of labelling (not shown).
Found at: doi:10.1371/journal.ppat.1001130.s005 (1.31 MB TIF)
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